Alpine Associates Management’s Apellis Pharmaceuticals APLS Stock Holding History

Alpine Associates Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-864,000	Closed	-$34.8M	–	71
2026 Q1	$34.8M	Buy	+864,000	New	+$18.6M	2.05%	13

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Alpine Associates Management's APLS Position: Q2 2026 in Review

Alpine Associates Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 864,000 shares — an estimated $34.8M sold.

Alpine Associates Management first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $34.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Alpine Associates Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Alpine Associates Management sold 864,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $34.8M.
Alpine Associates Management first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Alpine Associates Management's Apellis Pharmaceuticals position peaked at $34.8M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Alpine Associates Management's 13F filing for Q2 2026, filed 6 Aug 2026.